634 reports of this reaction
3.3% of all VILAZODONE HYDROCHLORIDE reports
#5 most reported adverse reaction
INSOMNIA is the #5 most commonly reported adverse reaction for VILAZODONE HYDROCHLORIDE, manufactured by Allergan, Inc.. There are 634 FDA adverse event reports linking VILAZODONE HYDROCHLORIDE to INSOMNIA. This represents approximately 3.3% of all 19,367 adverse event reports for this drug.
Patients taking VILAZODONE HYDROCHLORIDE who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is moderately reported among VILAZODONE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to insomnia, the following adverse reactions have been reported for VILAZODONE HYDROCHLORIDE:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 634 FDA reports for VILAZODONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 3.3% of all adverse event reports for VILAZODONE HYDROCHLORIDE, making it a notable side effect.
If you experience insomnia while taking VILAZODONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.